// App-Quantinova.ai

770 : Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors

Researchers

Presenter

  • Anthony Tolcher

Principal Investigators

  • Desamparados Roda-Perez

  • Kai He

  • Victor Moreno

  • Carlos Gomez-Roca

  • Jean-Pascal Machiels

  • Albiruni Razak

  • Mohammad Sahtout

  • Xiaowen Guan

  • Stacy Jaryno-Daly

  • Rachel Leibman

  • Martha Blaney

  • James O’Brien

  • Patricia LoRusso

  • John Powderly

  • Talia Golan

  • Kathy Miller

  • Jordi Bruix

Medical Centers

  • The James Cancer Hospital, Columbus, OH, USA

  • Carolina BioOncology Institute, Huntersville, NC

  • START Madrid-FJD, Madrid, Spain

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Yale Cancer Center, Yale University, New Haven, CT

  • Next Oncology, San Antonio/TX/US

  • The Institute of Cancer Research, London, UK

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Institut Claudius Regaud/IUCT Oncopole, Marseille, France

  • Institut Roi Albert II Cancer Centre, Brussels, Belgium

  • Chaim Sheba Medical Center, Tel Hashomer, Israel

  • Indiana University School of Medicine, Indianapolis, IN

Locations

  • United States

  • Canada

  • United Kingdom

  • Spain

  • France

  • Israel

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • First-In-Human

Phase

  • I

Study Id's

  • NCT03821935

Sponsors

  • Abbvie

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved